High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
- PMID: 22476854
- DOI: 10.1007/s10549-012-2039-z
High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study
Abstract
Monitoring of left ventricular ejection fraction (LVEF) is the current standard for detection of trastuzumab-induced cardiotoxicity; however, time-to-diagnosis and cost of assessment are suboptimal in women with early-stage breast cancer. We assessed the utility of B-type natriuretic peptide (BNP), high-sensitivity C-reactive protein (hs-CRP), and cardiac troponin I (cTnI) as serum biomarkers for early detection of trastuzumab-induced cardiotoxicity. Fifty-four women with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer were prospectively enrolled, and the relationship between elevated serum BNP, hs-CRP, and cTnI levels and clinically significant decreases in LVEF was examined. LVEF was monitored at 3-4 month intervals during trastuzumab treatment. Laboratory testing for candidate biomarkers was repeated every 3 weeks with each cycle of trastuzumab. Trastuzumab-induced cardiotoxicity was defined as a decrease in LVEF of ≥15% or to a value below 50%. A clinically significant decrease in LVEF was observed in 28.6% of women. Abnormal hs-CRP (≥3 mg/L) predicted decreased LVEF with a sensitivity of 92.9% (95% CI 66.1-99.8) and specificity of 45.7% (95% CI 28.8-63.4), and subjects with normal hs-CRP levels (<3 mg/L) have 94.1% negative predictive 94.1% (95% CI 70.3-99.9) suggesting that normal hs-CRP levels may be associated with low future risk for decreased LVEF; however, no association with BNP or cTnI was observed. A false positive would have a relatively low associated cost in breast cancer patients undergoing adjuvant trastuzumab therapy and would indicate continuation of routine observation during treatment through traditional means. The maximum hs-CRP value was observed a median of 78 days prior to detection of cardiotoxicity by decreased LVEF, and those with normal levels were at lower risk for cardiotoxicity. Regular monitoring of hs-CRP holds promise as a biomarker for identifying women with early-stage breast cancer at low risk for asymptomatic trastuzumab-induced cardiotoxicity. To our knowledge, this is the first study documenting the utility of a less expensive, reproducible, easily obtainable biomarker with rapid results for evaluating cardiotoxicity related to trastuzumab therapy.
Similar articles
-
Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.Asia Pac J Clin Oncol. 2011 Sep;7(3):276-80. doi: 10.1111/j.1743-7563.2011.01422.x. Asia Pac J Clin Oncol. 2011. PMID: 21884439
-
Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.Curr Med Res Opin. 2015 Mar;31(3):547-56. doi: 10.1185/03007995.2015.1005834. Epub 2015 Jan 27. Curr Med Res Opin. 2015. PMID: 25586297
-
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.Clin Cancer Res. 2011 May 15;17(10):3490-9. doi: 10.1158/1078-0432.CCR-10-1359. Epub 2011 Mar 3. Clin Cancer Res. 2011. PMID: 21372222 Clinical Trial.
-
Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.J Clin Oncol. 2007 Aug 10;25(23):3525-33. doi: 10.1200/JCO.2007.11.0106. J Clin Oncol. 2007. PMID: 17687157 Review.
-
Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.Adv Ther. 2009 Jul;26 Suppl 1:S9-17. doi: 10.1007/s12325-009-0048-z. Epub 2009 Jul 24. Adv Ther. 2009. PMID: 19669637 Review.
Cited by
-
Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers.Front Oncol. 2022 Oct 12;12:920867. doi: 10.3389/fonc.2022.920867. eCollection 2022. Front Oncol. 2022. PMID: 36313656 Free PMC article. Review.
-
Evaluating high-sensitivity cardiac troponin I for early detection of treatment-related cardiotoxicity in HER2-positive breast cancer patients.Ann Med Surg (Lond). 2025 Jan 9;87(1):93-102. doi: 10.1097/MS9.0000000000002753. eCollection 2025 Jan. Ann Med Surg (Lond). 2025. PMID: 40109639 Free PMC article.
-
Predicting doxorubicin-induced cardiotoxicity in breast cancer: leveraging machine learning with synthetic data.Med Biol Eng Comput. 2025 May;63(5):1535-1550. doi: 10.1007/s11517-025-03289-y. Epub 2025 Jan 20. Med Biol Eng Comput. 2025. PMID: 39828884
-
Low Preoperative albumin-to-globulin ratio Predict Poor Survival and Negatively Correlated with Fibrinogen in Resectable Esophageal Squamous Cell Carcinoma.J Cancer. 2017 Jul 2;8(10):1833-1842. doi: 10.7150/jca.19062. eCollection 2017. J Cancer. 2017. PMID: 28819381 Free PMC article.
-
Cardiac toxicity of trastuzumab in elderly patients with breast cancer.J Geriatr Cardiol. 2016 May;13(4):355-63. doi: 10.11909/j.issn.1671-5411.2016.04.003. J Geriatr Cardiol. 2016. PMID: 27403145 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous